Stemedica Wins License To Manufacture Stem Cells For Human Clinical Trials

Stemedica Cell Technologies (Stemedica) has been granted a license by the State of California’s Food & Drug Branch to manufacture stem cells for human clinical trials.

The Drug Manufacturing License recognizes Stemedica as being compliant with California law and the applicable provisions of the Code of Federal Regulations.

Roger Howe, executive chairman of Stemedica, said: This stamp of approval positions Stemedica as one of only a few companies in the world capable of manufacturing and delivering its own unique multiple cell products and factors. The company also has the ability to custom manufacture for select companies. These dynamic capabilities give us a significant point of advantage in the marketplace.

Maynard Howe, vice chairman and CEO of Stemedica, said: We’re very proud of the hard work, dedication and professionalism of the team that has made this possible. Their experience and expertise has been instrumental in assuring that our facility meets regulatory compliance requirements. With the approval and licensing process behind us we can now focus our efforts on manufacturing the highest quality stem cell products.